Leonardo Roever: Diagnosis and Management of Natural Anticoagulant Deficiencies
Leonardo Roever, CEO of Brazilian Evidence-Based Health Network, shared a post on LinkedIn about a recent article by Katarzyna Mayger et al, published in Journal of Thrombosis and Haemostasis, adding:
“Physiological anticoagulant deficiencies: pathogenesis, diagnosis, and clinical implications
Physiological anticoagulants are essential regulators of coagulation; their deficiency shifts hemostasis toward a pro-thrombotic state, increasing the risk of venous thromboembolism.
The main physiological anticoagulants—antithrombin (AT), protein C (PC), and protein S (PS)—operate via distinct mechanisms: AT directly inhibits active proteases, primarily thrombin and factor Xa, while PC inactivates activated factors V and VIII, with PS acting as a cofactor.
Deficiencies can be hereditary (resulting from genetic mutations) or acquired (resulting from reduced synthesis or increased consumption).”
Title: Physiological anticoagulant deficiencies: pathogenesis, diagnosis, and clinical implications
Authors: Katarzyna Mayger, Christelle Orlando, Beverley J. Hunt

Stay updated on all scientific advances with Hemostasis Today.
-
Aug 31, 2026, 15:13Nahid A. Qushmaq: MicroRNAs as Prognostic Biomarkers in Septic Patients
-
Aug 31, 2026, 14:32Mahir Khalil Ibrahim Jallo: Hot Topic From The ESC 2026 Munich
-
Aug 31, 2026, 14:28Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
-
Aug 31, 2026, 14:28Francisco Chacón-Lozsán: Should We Anticoagulate AF Patients With Only One Non-Sex Stroke Risk Factor?
-
Aug 31, 2026, 14:24Akl Fahed: Do Lifelong Differences in LDL Cholesterol Influence the Risk of Venous Thromboembolism?
-
Aug 31, 2026, 14:23Accelerating CAR-T Access Through Policy and System Reform – American Society of Hematology
-
Aug 31, 2026, 14:21Shirya Rashid: Does Bempedoic Acid Influence Venous Thromboembolism Risk?
-
Aug 31, 2026, 14:14Jason Andrade: SINGLE-AF Trial Validates Early Anticoagulation in AF
-
Aug 31, 2026, 14:07Ben Dowsing: Can Heart Failure Therapy Be Safely Withdrawn After HER2 Cardiotoxicity Recovery